NCT05491681View on ClinicalTrials.gov

AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
ARDS, Human
Interventions
BIOLOGICAL

intravenous delivery of allogeneic bone marrow-derived MSCs

MSCs

Sponsors

Lead Sponsor

BioCardia, Inc.
All Listed Sponsors
lead

BioCardia, Inc.

INDUSTRY